



Cognitive Vitality Reports[®] are reports written by neuroscientists at the Alzheimer's Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models.

XPro1595

Evidence Summary

XPro1595 inhibits soluble TNF specifically without affecting transmembrane TNF. Safety and efficacy will be determined when data from clinical trials become available.

Neuroprotective Benefit: XPro1595 treatment improved cognitive function and showed neuroprotective effects in various animal models. A phase 2 trial of XPro1595 in early Alzheimer's disease is scheduled to be completed in April 2025.

Aging and related health concerns: XPro1595 shows benefit in mouse models of cancer, cerebral ischemia, glaucoma, neuropathic pain, and spinal cord injury, but effects depend on the timing and route of treatment. There have not been any studies in humans.

Safety: No safety data from clinical trials in humans have been published in peer-reviewed journals to date.



Availability: in clinical development	Dose: Not established; ongoing clinical studies are testing a 1.0 mg/kg weekly subcutaneous dose.	Chemical formula: protein sequence can be found here
Half life: not documented	BBB: penetrant based on animal studies	
Clinical trials: Several are ongoing, but no results have been published to date.	Observational studies: none available	

What is it?

Tumor necrosis factor (TNF) comes in two forms, the transmembrane TNF (binding to TNFR2, playing a role in cell-cell contact) and soluble TNF (binding to TNFR1, producing action at a distance). Transmembrane TNF plays a role in neuroprotection, while soluble TNF is involved in pro-inflammatory functions, demyelination, and neurodegeneration. Anti-TNF antibodies (e.g., etanercept or Enbrel) block both the neuroprotective and neurodegenerative forms of TNF and have been associated with learning and memory impairment along with decreased neurogenesis ([Yli-Karjanmaa et al., 2019](#)). XPro1595 is a protein biologic under development by INmune Bio Inc., which selectively sequesters the soluble TNF by forming heterotrimers with native soluble TNF α ([Steed et al., 2003](#)). It is a PEGylated human TNF variant devoid of TNF receptor-binding activity. It is being developed for Alzheimer's disease and treatment-resistant depression ([inmunebio.com](#)).

Neuroprotective Benefit: XPro1595 treatment improved cognitive function and showed neuroprotective effects in various animal models. A phase 2 trial of XPro1595 in early Alzheimer's disease is scheduled to be completed in April 2025.

Types of evidence:

- Numerous laboratory studies

Human research to suggest prevention of dementia, prevention of decline, or improved cognitive function:

None available.

Human research to suggest benefits to patients with dementia:

No clinical trials of XPro1595 to date have had their results published in a peer-reviewed journal. Based on a press release from January 2021, a phase 1b open-label dose escalation study demonstrated that XPro1595 treatment (weekly s.c. injection) for 12 weeks reduced CSF levels of inflammation biomarkers (e.g., c-reactive protein, YKL-40)([inmunebio.com](https://www.inmunebio.com)). Results from this study have not been posted on ClinicalTrials.gov as of November 2024 ([NCT03943264](https://clinicaltrials.gov/ct2/show/study/NCT03943264)).

A phase 2 trial of XPro1595 in early Alzheimer's disease was initiated in 2022 and is ongoing, as of November 2024 ([NCT05318976](https://clinicaltrials.gov/ct2/show/study/NCT05318976)). In May 2022, the FDA requested additional information around Chemistry Manufacturing and Controls of the manufactured XPro1595, and placed the application to initiate the phase 2 trial in the US on clinical hold (while enrollment in Australia, Canada, and EU countries continued)([inmunebio.com](https://www.inmunebio.com)). In February 2024, the FDA lifted the clinical hold on the phase 2 trial ([alzheimersnews.today.com](https://www.alzheimersnews.today)). On November 13, 2024, INmune Bio Inc. announced completion of enrollment of 208 patients ([inmunebio.com](https://www.inmunebio.com)). The trial is scheduled to be completed in April 2025 ([NCT05318976](https://clinicaltrials.gov/ct2/show/study/NCT05318976)).

Mechanisms of action for neuroprotection identified from laboratory and clinical research:

XPro1595 has been studied in various animal and *in vitro* models. Subcutaneous XPro1595 treatment (10 mg/kg, s.c., every 3 days) achieved plasma levels of 1-8 µg/ml and CSF levels of 1-6 ng/mL, suggesting that XPro1595 reaches the brain ([Barnum et al., 2014](#)).

Aging model: In aged rats, treatment with XPro1595 (0.08 mg/kg/day into the lateral ventricle) for 4-6 weeks significantly improved cognitive function (measured by the Morris water maze), reduced microglial activation (decreased Iba-1 protein levels), reduced susceptibility to hippocampal long-term depression, increased protein levels of the GluA1 type glutamate receptor, and lowered L-type voltage-sensitive calcium channel activity in the hippocampal CA1 neurons ([Sama et al., 2012](#)). Protein levels for TNFR1 are elevated in the hippocampus relative to TNFR2 in aged but not young adult rats, suggesting that selective alterations in TNF signaling may drive age-related cognitive decline and synaptic dysfunction.

Alzheimer's disease models: XPro1595 has been tested in 3 mouse models of Alzheimer's disease. In 5xFAD mice, treatment with XPro1595 (10 mg/kg, twice weekly, subcutaneously) for 2 months reduced the age-dependent increase in activated immune cells, while decreasing the overall number of CD4+ T

cells and decreasing A β plaques in the subiculum ([MacPherson et al., 2017](#)). In brain slices of 5xFAD mice, XPro1595 treatment rescued the impairment in long-term potentiation. Treatment with XPro1595 for 2 months started at 5 months of age (onset of cognitive impairment) decreased the expression of pro-inflammatory genes in both 5xFAD mice and non-transgenic mice. CCL2 and TGF β are significantly decreased in 5xFAD mice, but IL-1 β and TNF failed to reach statistical significance.

In 5xFAD mice fed a high fat high carbohydrate diet, XPro1595 treatment (10 mg/kg, s.c.) twice a week for 4 weeks restored metabolic and inflammation indices only in male mice, measured by plasma insulin, glucagon, and IL-6 levels ([de Sousa Rodriguez et al., 2024](#)). XPro1595 treatment did not affect weight gain, gonadal weight, or liver weight in 5xFAD mice, compared with vehicle treatment.

In young adult 5xFAD mice fed a high fat high sugar diet, XPro1595 treatment (10 mg/kg, s.c.) twice a week for 4 weeks modulated peripheral and central immune profiles, including CNS-associated CD8+ T cells, the composition of gut microbiota, and synaptic plasticity measured by long-term potentiation ([MacPherson et al., 2023](#)). The high fat high sugar diet did not robustly increase amyloid deposition in the brains of young 5xFAD mice, and XPro1595 treatment had no significant effects on amyloid levels. XPro1595 treatment did not completely mitigate microgliosis in the hippocampus.

In an amyloid transgenic mouse model (TgCRND8 mice), treatment with XPro1595 (10 mg/kg, s.c.) started at 1 month of age for 4 weeks prevented synaptic deficits 4 months later at the age of 6 months ([Cavanagh et al., 2016](#)). In the inhibitory avoidance task, TgCRND8 mice treated with XPro1595 had latencies that were significantly lower than untreated TgCRND8 mice. In this mouse model, initiating treatment to block TNF- α prior to the onset of amyloid plaque formation prevented the hyperexcitability of glutamate synapses.

In another mouse model of Alzheimer's (3xTgAD mice), XPro1595 treatment (0.1 mg/kg/day, delivered to hippocampal CA1 with an osmotic pump) for 4 weeks significantly decreased the LPS-induced accumulation of A β in the hippocampus, cortex, and amygdala ([McAlpine et al., 2009](#)).

Parkinson's disease models: In a rat model of Parkinson's disease (6-OHDA hemiparkinsonian rats), XPro1595 treatment (10 mg/kg, s.c., every 3 days) for 35 days significantly reduced microglia and astrocyte number in substantia nigra pars compacta region, whereas loss of nigral dopaminergic neurons was attenuated when XPro1595 treatment was initiated 3 days after the 6-OHDA lesion, but not after 14 days post-lesion ([Barnum et al., 2014](#)).



In a monkey model of Parkinson's disease (escalating MPTP treatment), XPro1595 treatment (10 mg/kg, s.c., every 3 days) started on week 11 of MPTP lesion and continued onto week 40 failed to protect against nigrostriatal dopaminergic neuron loss ([Joers et al., 2020](#)). Other effects of XPro1595 were mixed and difficult to interpret due to sexually dimorphic responses and small sample sizes. For example, female monkeys displayed less reactive circulating cytokines compared to males, making it difficult to assess the immunomodulatory effects of XPro1595. Neutralization of soluble TNF with XPro1595 may have attenuated inflammation in biofluids and reduced CD68 expression (expressed by cells in the monocyte lineage, e.g., macrophages) in the colon. But there was early and robust increase in neuroinflammation as measured by PET TSPO prior to initiation of XPro1595 treatment, suggesting that the window for therapeutic benefit may have been missed in these monkeys. It is not known whether an earlier intervention with XPro1595 can afford more neuroprotection.

Huntington's disease models: In a mouse model of Huntington's disease (R6/2 mice), intracerebroventricular XPro1595 treatment (0.08 mg/kg/day, into the lateral ventricle) for 28 days starting at the age of 7 weeks decreased levels of TNF- α in the cortex and striatum, improved motor function, reduced caspase activation, decreased the amount of mutant HTT aggregates, increased neuronal density, and decreased gliosis ([Hsiao et al., 2014](#)). Systemic injection of XPro1595 (30 mg/kg, twice weekly, i.p.) at the ages of 7-15 weeks old improved the impaired motor function of R6/2 mice but did not affect caspase activation.

In vitro experiments showed that XPro1595 suppressed the inflammatory responses of primary astrocyte-enriched culture isolated from R6/2 mice and human astrocyte-enriched culture derived from induced pluripotent stem cells of Huntington's disease patients evoked by lipopolysaccharide and cytokines, respectively, while also protecting from cytokine-induced toxicity.

Multiple sclerosis models: In a mouse model of multiple sclerosis (experimental autoimmune encephalomyelitis; EAE), treatment with XPro1595 (10 mg/kg, every 3 days, s.c.) for 39 days (started on Day 16 of EAE when half of the mice reached a clinical score at or over 2 and until Day 55) significantly improved clinical outcome, preserved axons, improved myelin compaction, increased expression of axon-specific molecules (e.g., neurofilament-H), and decreased a protein associated with axon damage (non-phosphorylated neurofilament-H) ([Brambilla et al., 2011](#)). XPro1595-treated mice showed remyelination accompanied by increased numbers of oligodendrocyte precursors. GFAP protein, IFN- γ , TNF, IL-1 β , IL-6, CCL-2, CCL-5, CXCL-10, and CCR-2 were significantly decreased with XPro1595 treatment compared to the vehicle-treated. These findings suggest that selective inhibition of soluble TNF improves recovery following EAE, and that signaling pathways mediated by transmembrane TNF drives



the repair process. This is in contrast to non-selective TNF inhibitors, which are associated with demyelination.

In another mouse model of multiple sclerosis (cuprizone-fed mice), XPro1595 treatment (10 mg/kg, twice weekly, s.c.) did not prevent toxin-induced oligodendrocyte loss and demyelination, but resulted in early remyelination due to improved phagocytosis of myelin debris by CNS macrophages and prevention of disease-associated decline in motor performance ([Karamita et al., 2017](#)). Because these benefits with XPro1595 were absent in TNF-deficient mice and replicated in transmembrane TNF knock-in mice, transmembrane TNF appears to be sufficient for the maintenance of myelin and remyelination. XPro exerts neuroprotective effects by promoting early resolution of microgliosis in demyelinated lesions and increasing the clearance of myelin debris by phagocytic CNS macrophages, while promoting the synthesis of new myelin in demyelinated axons.

Other models: In a mouse model of type 2 diabetes (fed a high-fat high carbohydrate diet for 14 weeks), XPro1595 treatment (10 mg/kg, every 3 days, s.c.) for 11 weeks ameliorated hepatic metabolic disturbances, insulin resistance, and behavioral deficits (socialability deficits and anxiety-like behavior), while decreasing hepatic and intestinal levels of lipocalin-2, a marker of inflammation, ischemia, and kidney damage ([de Sousa Rodriguez et al., 2019](#); [Moschen et al., 2017](#)).

In a mouse model of traumatic brain injury (controlled cortical impact, unilaterally over the right parietal cortex), XPro1595 treatment (10 mg/kg, s.c.) 1 hour post-injury prevented cognitive impairment (measured by the Morris water maze), glial reactivity, neuronal dendritic degeneration (dendritic beading), and synapse loss (measured by spine density and PSD-95 expression) in the hippocampus ([Larson et al., 2022](#)). XPro1595-treated brain-injured mice were able to find the platform of the Morris water maze in the same amount of time and entered the same number of quadrants compared to sham-control mice (regardless of treatment).

APOE4 interactions: Unknown.

Aging and related health concerns: XPro1595 shows benefit in mouse models of cancer, cerebral ischemia, glaucoma, neuropathic pain, and spinal cord injury, but effects depend on the timing and route of treatment. There have not been any studies in humans.

Types of evidence:

- Numerous laboratory studies

XPro1595 has been studied in numerous animal models of age-related diseases. No data in humans have been published in peer-reviewed journals.

Cancer: BENEFIT IN MOUSE MODELS

In a mouse model of cancer (3-methylcholanthrene-induced carcinogenesis), XPro1595 treatment (200 µg/mL, i.p. twice weekly) for 12 weeks decreased tumor incidence and growth, prolonged survival of the mice, while decreasing IL-1 α and increasing IL-1 β , IL12p70, and IL-17 in the blood ([Sobo-Vujanovic et al., 2016](#)). In addition, XPro1595 treatment prevented accumulation of myeloid-derived suppressor cells, STAT3 phosphorylation, and immunosuppression in these mice. Based on studies of other mouse models (TNF-, TNFR1-, and TNFR2-deficient mice), soluble TNF is both an essential promoter of carcinogenesis and a pivotal regulator of myeloid-derived suppressor cells.

In a rat model of bone cancer pain (intratibial inoculation of Walker 256 mammary gland carcinoma cells), XPro1595 treatment (5, 10, and 20 mg/kg, intrathecal, every other day) from postoperative day 1-13 suppressed bone cancer-evoked glial activation and neuroinflammation ([Zhou et al., 2019](#)). These effects of XPro1595 were, at least partly, mediated by a reduction in the phosphorylation of p38 MAPK in spinal glial cells.

Cerebral ischemia: BENEFIT IN MOUSE MODEL WITH IMMEDIATE/LOCALIZED TREATMENT

In a mouse model of focal cerebral ischemia, (permanent middle cerebral artery occlusion), XPro1595 treatment (intravenously once, at a dose of 10 mg/kg) 30 minutes after occlusion significantly improved functional outcomes, altered microglial responses, decreased granulocyte infiltration into the brain, and modified the acute phase response, spleen T cell and microvesicle numbers, but without decreasing infarct volumes ([Clausen et al., 2014](#)). The protective effects of XPro1595 were comparable to those of etanercept, suggesting that soluble TNF is principally involved in the peripheral inflammation after stroke.

In a mouse model of focal cerebral ischemia (permanent middle cerebral artery occlusion), XPro1595 treatment into the infarct core (2.5 mg/ml/1 μ L/hour, mini-osmotic pump implanted 30 minutes after occlusion) for 1 or 3 consecutive days reduced infarct volume ([Yli-Karjanmaa et al., 2019](#)). However, intracerebroventricular treatment (1.25 mg/kg/0.5 ml, single dose) immediately after occlusion failed to reduce infarct volume. XPro1595 increased gene expression of P2RY12 and Trem2, while decreasing CX3CR1 expression after occlusion, suggesting a shift in microglial activation toward a phagocytic phenotype.

Glaucoma: BENEFIT IN A RAT MODEL

In a rat model of glaucoma, XPro1595 injection into the vitreous chamber (total volume of 5 μ L at 50 μ g/ μ L) protected the retinal ganglion cell soma and axons ([Cueva Vargas et al., 2015](#)). Retinal ganglion cell soma and axon/optic nerve survival were 94% and 81% with XPro1595 treatment, respectively, relative to intact control, whereas in vehicle-treated rats, survival was 66% and 46%, respectively. In this model, glia-derived soluble TNF- α , downregulation of GluA2 subunit of AMPA receptors, and upregulation of calcium-permeable AMPA receptor play a critical role in glaucomatous neurodegeneration.

Neuropathic pain: BENEFIT IN MALE MOUSE MODEL

In a mouse model of neuropathic pain (chronic peripheral nerve constriction injury), XPro1595 treatment (10 mg/kg, s.c., every 2 days) for 5 weeks significantly accelerated recovery from neuropathic pain in males, but not females ([Del Rivero et al., 2019](#)). In male mice, XPro1595 treatment reduces elevated NMDA receptor levels in the brain after injury, whereas in female mice, NMDA receptor levels decrease after nerve injury. It appears that estrogen inhibits the therapeutic response of XPro1595 in females, as ovariectomized mice that underwent the same injury showed reduction in allodynia, similar to responses observed in males.

Spinal cord injury: BENEFIT IN RODENT MODELS WHEN APPLIED DIRECTLY AND IMMEDIATELY AFTER INJURY

In a mouse model of moderate spinal cord injury (laminectomy between vertebrae T8 and T10, and an approximate displacement of 500 μ m), XPro1595 treatment (10 mg/kg, every 3 days, s.c., started 30 minutes after injury) for 8 weeks failed to improve locomotor performance ([Novrup et al., 2014](#)). In contrast, in the same mouse model, central administration of XPro1595 (2.5 mg/mL/1 μ L/hour, started immediately after injury) for 3 days resulted in improved locomotor function, decreased anxiety-related behavior, and reduced damage to the lesioned spinal cord. Central administration of etanercept (non-selective anti-TNF) showed no therapeutic benefits. Improvements in XPro1595-treated mice were



accompanied by increases in Toll-like receptor 4 and TNFR2 protein levels and changes in Iba1 protein expression in microglia/macrophages. Thus, protection is observed only when selective inhibition of soluble TNF is achieved directly to the lesioned cord immediately after injury.

In a mouse model of moderate spinal cord injury (moderate contusion injury at the ninth thoracic level), XPro1595 treatment for 3 days (2.5 ng/ml/1 μ L/h; continuously epidurally delivered with a micro-osmotic pump) transiently decreased pro-inflammatory interleukin IL-1 β and IL-6 levels and increased pro-regenerative, anti-inflammatory IL-10 levels in the acute phase after injury ([Lund et al., 2023](#)). On day 14 after injury, XPro1595-treated mice had significantly decreased number of infiltrated leukocytes (macrophages and neutrophils) in the lesioned area of the spinal cord and an increase in the number of microglia in the peri-lesion area. On day 21 after injury, XPro1595-treated mice had significantly decreased microglial activation. On day 35 after injury, XPro1595-treated mice had greater myelin preservation (measured by myelin basic protein levels) and improved functional outcomes compared to vehicle-treated mice. Myelin basic protein levels also significantly correlated with improved functional outcomes. XPro1595 treatment did not affect the spatiotemporal expression of TNF receptors after spinal cord injury.

After a severe, high-level spinal cord injury, heightened spinal sympathetic reflex activity can detrimentally impact peripheral organ systems, causing episodes of autonomic dysreflexia, a life-threatening condition characterized by sudden hypertension and reflexive bradycardia following below-level sensory inputs ([O'Reilly et al., 2021](#)). The frequency and severity of such events increase greatly beginning several weeks post-injury. People who have experienced spinal cord injury are susceptible to cardiovascular disease and infections, which are leading causes of morbidity and mortality.

In female rats subjected to autonomic dysreflexia in high-level spinal cord injury (dorsal laminectomy of T3), XPro1595 treatment (intrathecal, 60 μ g/day via osmotic minipumps at the lesion epicenter) decreased the frequency and severity of autonomic dysreflexia episodes (measured by autonomic dysreflexia events and peak blood pressure and duration per autonomic dysreflexia event) ([Mironets et al., 2018](#)). This was mediated by decreased sprouting of nociceptive primary afferents and activation of the spinal sympathetic reflex circuit. pNF-kB p65 is significantly elevated in rats subjected to spinal cord injury, but intrathecal XPro1595 treatment lowered this to levels comparable to naïve rats. XPro1595 treatment also slightly decreased TNFR1 levels in the lumbar spinal cord. XPro1595 treatment did not affect basal hemodynamics (baseline mean arterial pressure or baseline heart rate).

In rats subjected to high thoracic spinal cord injury, intrathecal XPro1595 treatment started at 2 weeks post-injury and continued for 42 days failed to attenuate the severity or intensification of sympathetic hyperreflexia compared with vehicle-treated controls ([O'Reilly et al., 2021](#)). These findings suggest that central soluble TNF- α signaling needs to be inhibited sooner after injury in order to decrease sympathetic hyperreflexia.

COVID-19: NO BENEFIT

A phase 2/3 clinical trial tested whether XPro1595 treatment (up to 2 once per week subcutaneous injections of 1 mg/kg) can prevent the progression of respiratory complications in 79 COVID-19 patients ([NCT04370236](#)). This trial was started in October 2020 and was terminated in November 2021 due to futility.

Safety: No safety data from clinical trials in humans have been published in peer-reviewed journals to date.

Types of evidence:

- Numerous laboratory studies

A phase Ib study of XPro1595 in patients with mild to moderate Alzheimer's disease was completed in September 2021 ([NCT03943264](#)). It was an open-label study that enrolled 20 participants to determine the optimal dose of XPro1595 (0.3, 0.6, and 1.0 mg/kg via subcutaneous injection once a week for 12 weeks). The primary outcome was the number and percentage of patients with treatment-emergent adverse events throughout the 12 weeks of treatment with XPro1595. Results from this phase I study have not been published in a peer-reviewed journal, or posted on ClinicalTrials.gov as of November 2024.

In a rat model of spinal cord injury (T9 contusive injury), XPro1595 treatment (10 mg/kg, every 3 days, s.c.) started at the time of injury caused an exacerbation of depressive phenotype (assessed by forced swim immobility) seen in greater than 50% of female rats subjected to spinal cord injury ([Farrell and Houle, 2019](#)). There was a positive correlation between increased TNF levels in the dorsal raphe nucleus after thoracic spinal cord injury, but targeting this increase failed to reduce the depressive phenotype, and instead, exacerbated the incidence of depression. Whether or not XPro1595 treatment produces similar effects in people is not yet known.

In young adult 5xFAD mice fed a high fat high sugar diet, XPro1595 treatment (10 mg/kg, s.c.) twice a week for 4 weeks had no effects on liver, cecum, gonadal, or retroperitoneal fat pad weight ([MacPherson et al., 2023](#)).

Drug interactions: Drug interactions have not been studied to date. Based on XPro1595's mechanism of action, it is likely to interact with medications that target the TNF or other immune modulators.

Sources and dosing:

XPro1595 is under development by INmune Bio Inc. It is being developed for Alzheimer's disease and treatment-resistant depression ([inmunebio.com](#)). Ongoing clinical trials are testing a dose of 1.0 mg/kg XPro1595 given subcutaneously once a week ([NCT05318976](#)). In mouse studies, the typical dose is 10 mg/kg, subcutaneously, every 3 days ([de Sousa Rodriguez et al., 2019](#); [Yli-Karjanmaa et al., 2019](#)).

Research underway:

There are currently 2 clinical trials testing XPro1595. A phase 2 double-blind randomized controlled trial is studying whether a 1.0 mg/kg XPro1595 treatment (s.c., once a week) for 23 weeks confers a benefit on cognition, function, and biomarkers of white matter in 201 people with early Alzheimer's disease (mild cognitive impairment or mild Alzheimer's disease) with a biomarker evidence of inflammation ([NCT05318976](#)). The primary outcome is change in early and mild Alzheimer's cognitive composite (EMACC) from baseline to week 24. Enrollment of 208 patients was completed in November 2024, ([inmunebio.com](#)). This study is estimated to be completed in April 2025. The other ongoing study is an open-label extension of XPro1595 in people with Alzheimer's disease ([NCT05522387](#)). This study is aiming to evaluate the long-term safety, tolerability, and efficacy of XPro1595. Each enrolled patient will receive a total exposure of XPro1595 for up to 78 weeks, depending on the length/randomization of their previous study. This study is estimated to be completed in December 2024.

The [NIH](#) is supporting several programs testing XPro1595: one is studying its effects on inflammation-related deficits in reward circuitry and motivation in depression ([R44MH125480](#)), another program is studying its effects on cardiovascular and immune function after spinal cord injury ([R01NS122371](#)), and another program is studying its effects on anhedonia and psychomotor function in people with HIV ([R01MH128872](#)).



Search terms:

Pubmed, Google: XPro1595, INB03, XENP1595, DN-TNF, XENP345, pegipanermin

Websites visited for XPro1595:

- [Clinicaltrials.gov](https://clinicaltrials.gov)
- [NIH RePORTER](https://reporter.nih.gov)
- DrugAge (0)
- Geroprotectors (0)
- Drugs.com (0)
- WebMD.com (0)
- [PubChem](https://pubchem.ncbi.nlm.nih.gov)
- [DrugBank.ca](https://drugbank.ca)
- [GSRs.NCATS.NIH.gov](https://gsrs.ncats.nih.gov)
- Cafepharm (0)
- Pharmapro.com (0)

Disclaimer: Cognitive Vitality Reports® do not provide, and should not be used for, medical advice, diagnosis, or treatment. You should consult with your healthcare providers when making decisions regarding your health. Your use of these reports constitutes your agreement to the [Terms & Conditions](#).

If you have suggestions for drugs, drugs-in-development, supplements, nutraceuticals, or food/drink with neuroprotective properties that warrant in-depth reviews by ADDF's Aging and Alzheimer's Prevention Program, please contact INFO@alzdiscovery.org. To view our official ratings, visit [Cognitive Vitality's Rating page](#).